Pregnenolone and Progesterone for Men: Pharmacokinetics and Studies

[Gianluca]

I have bad news to report about my experience with pregnenolone (100 mg per night up to 300 mg per night).

During the past few months while using it I had to up my dose of blood pressure meds since my BP was increasing dramatically (no changes in weight, stress, hormones, etc).

I decided to stop the pregnenolone and 2 days later my BP was back to baseline. That has remained so for two weeks even as I scaled back my HTN treatment.

Pregnenolone can potentially have an effect on aldosterone and cortisol. I am not sure if this explains my increased BP.


View attachment 18887

I will report in a few weeks to make sure this is not just a coincidence.

do you think perhaps Pregnenolone caused you some water retention?

 

[Anonymon]

do you think perhaps Pregnenolone caused you some water retention?

It immediately does for me, which in my case was welcome. I’ve taken fludrocortisone before, and the results were similar without the more negative side effects I experienced, like cramping from potassium loss. Immediately, same day, at 200mg+ I’ll retain more water.

 

[Gianluca]

It immediately does for me, which in my case was welcome. I’ve taken fludrocortisone before, and the results were similar without the more negative side effects I experienced, like cramping from potassium loss. Immediately, same day, at 200mg+ I’ll retain more water.

What type of Pregnenolone are you using?

 

[Anonymon]

What type of Pregnenolone are you using?

Always the micronized kind in capsule/tabletish form, seemingly all from wild yam. I’ve used a bunch of different kinds of the better brands. Right now on Klaire Labs and before that Allergy Research and there were a couple of others. All had the same results. Klaire Labs so far has been my favorite for price point vs effectiveness and they’ve always been a good brand for me. Once in the morning, 400mg. One of the more expensive things I do but it helps a lot when combined with T3.

 

[Nelson Vergel]

do you think perhaps Pregnenolone caused you some water retention?

I weigh myself every day. No weight gain on 100-300 mg per day of pregnenolone. Very strange. The reason I find out I have high BP is ringing in my ears. I have a great BP monitor at home.

Testosterone and Men’s Health Forum

The Best Men's Health and Testosterone Forum Focusing on TRT, ED, hCG, Anastrozole, Thyroid, Libido, Mood, Exercise, Nutrition and Productivity in Men.

www.excelmale.com

 

[DragonBits]

I have bad news to report about my experience with pregnenolone (100 mg per night up to 300 mg per night).

During the past few months while using it I had to up my dose of blood pressure meds since my BP was increasing dramatically (no changes in weight, stress, hormones, etc).

I decided to stop the pregnenolone and 2 days later my BP was back to baseline. That has remained so for two weeks even as I scaled back my HTN treatment.

Pregnenolone can potentially have an effect on aldosterone and cortisol. I am not sure if this explains my increased BP.


View attachment 18887

I will report in a few weeks to make sure this is not just a coincidence.

My main problem from supplements was very agitated sleep. But my baseline blood pressure kept moving up, and spikes up got serious, like 190/110. I felt like I had to pee more, and had a craving for things with calcium, like milk.

**1) AREDS 2
**2) Boron (calcium borogluconate) 6 mg
**3) Koncentrated K Vitamin K1 (Phylloquinone 5mg) Vitamins MK4 (Menaquinone 4, 25 mg) and MK7 (Menaquinone 7, 0.5 mg) Astaxanthin (2 mg)
**4) Magtein magnesium l-threonate 1 tabs 11% DV
5) Vitamin B-12 1000 MCG, 16,666 %DV
6) 2x CO Q-10 100 mg NewRhythm Probiotics
**7) Vitamin D3 10,000 IU every other day
8) Super Bio-Curcumin®NIH Curcumin
9) DHEA 25 mg
10) Pregnenolone 50 mg

While taking these supplements, my sleep was extremely agitated besides my blood pressure moving up.

Now I am sleeping much better, still get up but not to hard to fall back to sleep. The ** I restarted a few days ago, so we shall see. The pregnenolone I had been using 25mg, but started to use 50 mgs 6 months or so ago.

In June of 2020, I tested pregnenolone blood levels, it was 37 ng/dl (170-200).

I have no doubt that combination of supplements was causing serious problems, but not at all certain which one/s.

Some hormones, like dhea, it doesn't take a lot to push up my levels, while others like estrogen is never high as I have a modest conversion factor, the only thing that really affected estrogen was clomid.

I feel like my short term memory isn't as good but that is a bit subjective. My main suspect to cause me troubles was the pregnonlone.

 

[Gianluca]

Neuroactive steroids and anxiety disorders​

Introduction​

The classic mechanism of action of steroid hormones involves binding to their respective intracellular receptors, which act as transcription factors in the regulation of gene expression. The ensuing effects, described as the genomic effects of steroids, are relatively slow. Evidence that some steroids, through interaction with certain neurotransmitter receptors, can alter neuronal excitability at the cell surface has led to the description of the rapid membrane effects of steroids. The term “neuroactive steroid” (NAS) has been coined for steroids with these particular properties.1 Diverse mechanisms for rapid steroid effects have now been described, and the nongenomic effects of NASs may involve γ-aminobutyric acid (GABA) receptors, glutamate receptors, nicotinic acetylcholine receptors, sigma receptors, 5-HT3 receptors, or voltage- or non-voltage-gated calcium channels. These various mechanisms are reportedly involved in functions as diverse as sleep, anxiety, seizure activity, aggressive behaviour, response to stress, and neuronal regeneration and protection, as well as in learning and memory.2
Go to:

Neuroactive steroids, the GABAA receptor complex and anxiety​

The bulk of research on the role of NASs in anxiety and stress involves the GABAA receptor complex, at which several NASs act as positive or negative allosteric modulators. NASs that affect GABAA receptor function include progesterone derivatives such as allopregnanolone (ALLO; 3α,5α-tetrahydroprogesterone), epiallopregnanolone (3β,5α-tetrahydroprogesterone), pregnanolone (3α,5β-tetrahydroprogesterone), and tetrahydrodeoxycorticosterone (3α,5α-THDOC), as well as pregnenolone (PREG), pregnenolone sulfate (PREGS), dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Such modulation suggests a direct binding site (or sites) for the NAS on the GABAA receptor, although such sites have not yet been unequivocally demonstrated. These NASs can be synthesized de novo in the nervous system (in which case they are called neurosteroids3), the adrenals, the gonads and the placenta. Of these NASs, only 3α,5α-THDOC is not considered a neurosteroid stricto sensu because, although it is produced in the brain from deoxycorticosterone, it becomes undetectable in that organ after adrenalectomy. Enzymes involved in the biosynthesis of these NASs, such as 5α-reductase and 3α-hydroxysteroid oxidoreductase, are found in key neuroanatomic structures involved in anxiety such as the amygdala and the hippocampus.4
The endogenous 3α-hydroxy ring A-reduced steroids such as ALLO and 3α,5α-THDOC are among the most potent ligands of the GABAA receptor, with affinities equal to or greater than those of other known ligands such as benzodiazepines or barbiturates.5 In animal models of anxiety, positive modulation of the GABAA receptor has been associated with anxiolytic activity, whereas negative modulation has been associated with anxiogenic activity.6 Indeed, in most, but not all, studies involving several animal models, peripheral and central administration of ALLO, 3α,5α-THDOC and, to a lesser extent, PREG has resulted in significant anxiolytic activity.6,7 ALLO also appears to be responsible for the observed anxiolytic activity of progesterone. Bitran et al7 showed that administration of progesterone is associated with increases in serum and cortical levels of ALLO and that the anxiolytic activity of progesterone was due to its conversion to ALLO.
The effects on anxiety of PREG, PREGS, DHEA and DHEAS are less clear than those of ALLO. PREG has been reported to induce anxiogenic activity in mice tested in the plus-maze model.8 In the same study, PREGS produced a biphasic action, with a low dose (in the nanomolar range) inducing anxiolytic effects and a high dose (in the micromolar range) an anxiogenic response. Contradictory results have been obtained with PREGS, which may reflect the mixed agonist–antagonist profile observed at the level of GABAA receptor function.9 However, these results could also be explained by the positive allosteric modulator activity of PREGS at the level of the N-methyl-D-aspartate (NMDA) excitatory amino acid receptor, given that antagonist activity at the level of this receptor is associated with anxiolytic activity.10 Observed anxiogenic activity of DHEAS in mice undergoing the mirror chamber behavioural test is consistent with its antagonist properties at the level of the GABAA receptor.11 However, in studies with the plus-maze model in mice, DHEA and DHEAS both produced anxiolytic effects.12 Interestingly, DHEAS can block the anxiolytic activity of dizocilpine, an NMDA receptor antagonist, in the mirror chamber test, which suggests that the effects of DHEA and DHEAS on anxiety might be mediated through mechanisms independent of GABAA receptor activity.11
Go to:

Clinical studies on neuroactive steroids​

NASs, particularly ALLO and pregnanolone, are reportedly decreased in both the cerebrospinal fluid (CSF) and the plasma of untreated patients with major depressive episode.13,14 Antidepressant treatment with the selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine, also used to treat anxiety disorders, normalized the ALLO and pregnanolone content of the CSF, and there was a correlation between improvements in symptoms and increase in CSF levels of ALLO and pregnanolone.15 Interestingly, Romeo et al13 found a chronological association between SSRI-induced increases in plasma ALLO and the classically delayed clinical response to antidepressant treatment (also true for the clinical response to the anxiolytic activity of SSRIs). The SSRIs have also been reported to alter the enzymatic activity of the 3α-hydroxysteroid oxidoreductase.15,16
To the best of our knowledge, we have performed the first studies assessing plasma levels of NAS derivatives of progesterone in patients with anxiety disorders, namely generalized anxiety disorder, generalized social phobia and panic disorder. Contrary to our hypotheses, we did not find any clear differences in baseline plasma levels of ALLO between patients with generalized anxiety disorder,17 generalized social phobia18 or panic disorder (unpublished data) and normal subjects. This last result contradicts a recently published paper which described higher ALLO levels in patients with panic disorder.19 Interestingly, we found that patients with generalized anxiety disorder or generalized social phobia but not panic disorder had lower plasma levels of PREGS than healthy volunteers. However, we did not find any correlation between plasma levels of PREGS and the severity of symptoms, as assessed with the Hamilton Anxiety and the Liebowitz Social Anxiety scales in patients with generalized anxiety disorder or generalized social phobia respectively. Given the lack of correlation between PREGS levels and symptom severity, the lower levels of PREGS may represent insufficiency of a compensatory mechanism. Since PREGS is anxiolytic at low doses (through agonist activity at the level of the GABAA receptor) but anxiogenic at high doses (through antagonist activity at the level of the same receptor), the observed lower levels of PREGS could be interpreted as an attempt to cope with pathologic anxiety by counteracting the detrimental antagonist activity of PREGS at the level of the GABAA receptor. In addition, data from animal studies suggest that the anxiogenic activity of PREGS can also be mediated by its positive allosteric modulator activity at the level of the NMDA excitatory amino acid receptor,20 which is in accordance with the anxiogenic activity associated with increased glutamatergic activity.10
If the lack of pathologic anxiety is considered the result of a homeostatic balance between endogenous anxiolytic and anxiogenic agents and more particularly is determined to represent an equilibrium between GABAergic and glutamatergic activity,8 the body would be able to maintain homeostasis through fluctuations in the intensity of GABAergic and glutamatergic function. In the context of pathologic anxiety, lower production of PREGS could be interpreted as a homeostatic attempt to decrease anxiogenic activity through a lesser negative modulation of the GABAA receptor and a lesser positive modulation of the NMDA receptor. Spivak et al21 found that plasma levels of DHEA and DHEAS were higher than normal in male patients with combat-related posttraumatic stress disorder; however, we did not find any such changes in patients with generalized anxiety disorder, generalized social phobia or panic disorder.
Go to:

Neuroactive steroids and the hypothalamic-pituitary-adrenal axis​

Several animal studies have shown that various stressors induce a delayed increase in brain and plasma concentrations of ALLO and 3α,5α -THDOC, 2 positive modulators of the GABAA receptor.22,23 These stress paradigms were associated with an initial increase in binding of tert-butylbicyclophosphorothionate labelled with sulphur-35, a sensitive marker of GABAA receptor function; the increased binding was interpreted by Barbaccia et al23 as a consequence of decreased GABAergic transmission. One of the stress paradigms used in male rats was inhalation of carbon dioxide, a challenge known to induce anxiety-like behaviour in rats and panic attacks in humans.23 Our pilot data in men with panic disorder and healthy volunteers, which showed a strong trend toward greater levels of ALLO (almost reaching statistical significance [p = 0.08]), suggest that challenge with the panicogenic agent pentagastrin may also induce a delayed release of ALLO in plasma.24
This stress- or panic-induced release of NASs has been speculated to represent an endogenous homeostatic mechanism for restoring the GABAergic system after stress23 as well as for restoring normal activity of the hypothalamic-pituitary-adrenal (HPA) axis. Interpretation of this delayed increase in ALLO (and likely 3α,5α-THDOC) as a protective homeostatic mechanism against stress is supported by the effects of ALLO and 3α,5α-THDOC on HPA axis activity and the well-known inhibitory effects of GABAA receptor activity on HPA axis activity.25 For example, peripheral administration of ALLO and 3α,5α-THDOC to rats dampened the activity of the HPA axis in response to stress.26,27
Subcutaneous administration of ALLO lessened the release of corticosterone in response to air puffs (a stress test) in adult male rats and decreased gene transcription of arginine vasopressin, a secretagogue of adrenocorticotropic hormone, in the hypothalamus.27 Subcutaneous administration of 3α,5α-THDOC attenuated the long-lasting HPA axis-related alterations -associated with maternal separation in infant male rats. Indeed, administration of 3α,5α-THDOC to male rat pups before separation from their mothers counteracted the exaggerated adrenocortical (cortiscosterone) response to emotional stress, the decreased responsiveness to the suppressive action of dexamethasone, the increased levels of corticotropin-releasing hormone messenger RNA in the paraventricular nucleus and the diminished numbers of glucocorticoid receptor-encoding transcripts in the hippocampus.28 Such inhibitory effects of these NAS GABAA agonists are not surprising, since other positive allosteric modulators of the GABAA receptor such as benzodiazepines inhibit baseline and post-challenge HPA axis activity in rodents as well as in healthy human volunteers and patients with panic disorder.29,30,31
We are therefore proposing that there is a full-loop homeostatic control mechanism between the HPA axis and the NAS system during stress, with a paramount negative feedback of NASs released after stress on the increased HPA axis activity displayed during stress. This interpretation fits the relatively new concept of allostasis and allostatic load described by McEwen and Seeman32 and suggests that NASs may play an important role in this multidimensional extension of the stress concept. This concept is based on the fact that release of certain hormonal mediators such as glucocorticoids and catecholamines are essential for adaptation, maintenance of homeostatis and survival in the short term in response to acute stress (allostasis), but if this release of “stress” hormones persists, they might be harmful, inducing a disease process (allostatic load). We believe that it is essential to continue investigating the release of NASs in response to stress in humans because data suggest that such release, particularly the release of positive allosteric modulators of the GABAA receptor, contribute (in association with, for example, cortisol negative feedback) to the extinction of the allostatic mechanisms after termination of an acute stressor. This release of NASs therefore prevents the development of deleterious effects (allostatic load) that would be associated with the persistence of the biological response to stress and, hence, prevents its deleterious effect on health.
Go to:

Conclusions​

There are now preliminary clinical data to support the results of animal investigations that have suggested a role of NASs in anxiety and therefore a potential role for NAS analogues in the treatment of anxiety disorders. Our results and those of others suggest that anxiety disorders have in common some NAS dysregulations but that each anxiety disorder may display its own specific pattern of dysregulation. A global interpretation of the role of human NASs in anxiety disorders will be facilitated by extensive measurements of various NASs since the effect of a decrease in one NAS may be offset by an increase in another one with similar activity at the level of the GABAA receptor.33 Given the efficacy of SSRIs in the treatment of most anxiety disorders and their ability to alter the enzyme kinetics involved in NAS metabolism, it will also be important to assess whether successful treatment with SSRIs is associated with normalization of the NAS dysregulation observed in patients with anxiety disorders.
The crucial role that NASs seem to play in preventing a chronic allostatic load suggests that their importance extends beyond mental health and that NAS dysregulation may be a unique link in the now well described association between physical health and mental health.

Neuroactive steroids and anxiety disorders - PMC

www.ncbi.nlm.nih.gov

 

[Gianluca]

Progesterone-induced changes in sleep in male subjects​

Abstract​

Progesterone administration induces a reduction of the vigilance state in humans during wakefulness. It has been been suggested that this effect is mediated via neuroactive metabolites that interact with the gamma-aminobutyric, acidA (GABAA) receptor complex. To investigate the effects of progesterone administration on the sleep electroencephalogram (EEG) in humans we made polysomnographic recordings, including sleep stage-specific spectral analysis, and concomitantly measured plasma concentrations of progesterone and its GABA-active metabolites 3 alpha-hydroxy-5 alpha-dihydroprogesterone (allopregnanolone) and 3 alpha-hydroxy-5 beta-dihydroprogesterone (pregnanolone) in nine healthy male subjects in a double-blind placebo-controlled crossover study. Progesterone administration at 9:30 PM induced a significant increase in the amount of non-rapid eye movement (REM) sleep. The EEG spectral power during non-REM sleep showed a significant decrease in the slow wave frequency range (0.4-4.3 Hz), whereas the spectral power in the higher frequency range (> 15 Hz) tended to be elevated. Some of the observed changes in sleep architecture and sleep-EEG power spectra are similar to those induced by agonistic modulators of the GABAA receptor complex and appear to be mediated in part via the conversion of progesterone into its GABA-active metabolites.

Progesterone-induced changes in sleep in male subjects - PubMed

Progesterone administration induces a reduction of the vigilance state in humans during wakefulness. It has been been suggested that this effect is mediated via neuroactive metabolites that interact with the gamma-aminobutyric, acidA (GABAA) receptor complex. To investigate the effects of...

pubmed.ncbi.nlm.nih.gov

 

[tropicaldaze1950]

It was anti anxiety for me. Gave me a clearer head and helped me sleep at first. Then theses benefits seemed to fade after about 2 weeks. Also, all my numbers went up including estrogen and estradiol, having a negative affect on my libido. So I quit.

I keep coming back to this thread because the information and discussions are quite informative and insightful. I just started to experiment, again, with progesterone(Progestelle, in olive oil) to improve sleep, in order to get off of clonazepam. Also, like many, I've been influenced by the late Ray Peat's research on pregnenolone. Regarding pregnenolone, what about cycling it, weekly, in one dose? Peat said a single oral dose recycles for about a week.

Several years ago I was taking 1 gm in olive oil, nightly, for sleep. In the short run it improved sleep but it also worsened reflux likely by relaxing the pyloric valve and I also couldn't ejaculate. I want to believe there's a sweet spot regarding dosing and perhaps for some of us, taking it weekly might help achieve that.

 

[Gianluca]

I keep coming back to this thread because the information and discussions are quite informative and insightful. I just started to experiment, again, with progesterone(Progestelle, in olive oil) to improve sleep, in order to get off of clonazepam. Also, like many, I've been influenced by the late Ray Peat's research on pregnenolone. Regarding pregnenolone, what about cycling it, weekly, in one dose? Peat said a single oral dose recycles for about a week.

Several years ago I was taking 1 gm in olive oil, nightly, for sleep. In the short run it improved sleep but it also worsened reflux likely by relaxing the pyloric valve and I also couldn't ejaculate. I want to believe there's a sweet spot regarding dosing and perhaps for some of us, taking it weekly might help achieve that.

Pregnenolone-S has a half life of 16/8 hr, so it may not make sense to take it once per week unless a bigger dose is taken. A smaller dose like 25/50mg daily makes more sense to me.

 

[SSHSSA74]

I keep coming back to this thread because the information and discussions are quite informative and insightful. I just started to experiment, again, with progesterone(Progestelle, in olive oil) to improve sleep, in order to get off of clonazepam. Also, like many, I've been influenced by the late Ray Peat's research on pregnenolone. Regarding pregnenolone, what about cycling it, weekly, in one dose? Peat said a single oral dose recycles for about a week.

Several years ago I was taking 1 gm in olive oil, nightly, for sleep. In the short run it improved sleep but it also worsened reflux likely by relaxing the pyloric valve and I also couldn't ejaculate. I want to believe there's a sweet spot regarding dosing and perhaps for some of us, taking it weekly might help achieve that.

Maybe I will try the one week cycle.